article thumbnail

Reasonable Pricing Clauses: A First Step Toward Ensuring Taxpayers a Fair Return on their Public R&D Investment

Bill of Health

Senator Sanders’ proposal within PAHPA was ultimately struck from the next iteration of the legislation due to concerns from the pharmaceutical industry and others that such a measure would chill innovation. Federal support by BARDA and the CDC have de-risked the development of medical products for the pharmaceutical industry.

COVID-19 205
article thumbnail

Can Rights Make Any Difference for Access to Health? Insights from a Scoping Review on Constitutional Rights for the WHO Council on the Economics of Health for All

Bill of Health

By Luciano Bottini Filho, Camila Gianella Malca, and Alicia Ely Yamin The intersection of health financing and the right to health is a common concern in public health advocacy. However, it is challenging to isolate the mechanisms that connect individuals’ rights with increased public investment.

Bioethics 326
article thumbnail

The Remarkable Rise of Pharma’s Reputation in the Pandemic

Health Populi

The reputation of the pharmaceutical industry gained a “whopping” 30 points between January 2020 and February 2021, based on the latest Harris Poll in their research into industries’ reputations. The study was written up by Beth Snyder Bulik in FiercePharma. The coronavirus re-shaped people in the U.S.

COVID-19 154